Institutions collaborate to license out C2c1 and C2c2 systems for commercial use
Skolkovo Institute of Science and Technology “Skoltech” is announcing a joint invention administration agreement (JIAA) with the Broad Institute of MIT and Harvard and with Rutgers, The State University of New Jersey, to make jointly-developed CRISPR intellectual property (IP) available to the commercial scientific and biotechnology communities.
The IP, which is also co-owned by Harvard University and the Massachusetts Institute of Technology (MIT), relates to CRISPR systems referred to as C2c1 (Cas12b) and C2c2 (Cas13). Beginning in 2015, a team of researchers from the collaborating institutions announced the discovery and characterization of these CRISPR systems.
This international cooperative effort has strengthened the understanding and availability of CRISPR biological science. In particular, the CRISPR C2c2 system provides an important addition to the suite of molecular biology tools, allowing for targeting of RNA, which helps with crucial steps in protein synthesis, for example.
“Skoltech is very proud of its cooperation with Rutgers, the Broad Institute and many others,” said Professor Alexander Kuleshov, Skoltech President. “Together, we are creating commercially viable technology which can benefit mankind. We look forward to fostering these relationships.”
“This technology represents a transformative opportunity to improve human health,” said Issi Rozen, chief business officer of the Broad Institute. “We are proud to partner with Skoltech and many other collaborating institutions to share these tools openly.”
“CRISPR technology has truly revolutionized how scientists think about disease and is helping researchers advance efforts to improve human health and outcomes for people across the world,” said David Kimball, Interim Senior Vice President for Research and Economic Development at Rutgers University. “We are proud to be partnering with institutions deep-rooted in the culture of research and discovery such as Skoltech, the Broad Institute, and others on this collective effort to bring new innovations to the research community.”
+7 (495) 280 14 81